OliX Pharmaceuticals is moving beyond the liver to own the “non-liver” RNAi delivery platforms of the future. Its strategy is focused on cp-asiRNA for local delivery, GalNAc for metabolic precision, and BBB-shuttles for CNS targeting.
1. The “cp-asiRNA” Advantage (Ophthalmic & Dermatology)
While traditional siRNA requires complex delivery vehicles like LNPs, OliX utilizes a proprietary asymmetric structure for superior tissue penetration.
- Structural Innovation: The cell-penetrating asymmetric siRNA (cp-asiRNA) minimizes off-target effects and enables self-delivery into local tissues.
- OLX301A (Dry & Wet AMD): By targeting the source of protein production in the eye, this platform aims to extend treatment intervals significantly beyond current Anti-VEGF standards. It ensures long-term safety without the inflammatory risks associated with nanoparticle-based delivery.
2. GalNAc-asiRNA: Precision Metabolic Control
OliX’s GalNAc platform is the foundation of its high-stakes collaboration with Eli Lilly, focusing on genetic targets that traditional small molecules cannot reach.
- OLX702A (MARC1 Targeting): Unlike weight-loss-only drugs, OLX702A focuses on direct liver protection. By silencing the MARC1 gene, it acts as a genetic shield against fibrosis and MASH (NASH).
- Combination Potential: As MASH is a multi-factorial disease, OliX’s RNAi is being developed to work alongside GLP-1 agonists (Zepbound/Wegovy), providing a dual-layered approach to metabolic health.
3. CNS Expansion & BBB-Shuttle Integration
In 2026, OliX is unlocking the “undruggable” brain through its newly integrated delivery platforms.
- BBB-Shuttle Technology: By integrating Blood-Brain Barrier (BBB) shuttles from partners like Key2Brain, OliX can now deliver gene-silencing therapies to the brain.
- Neurodegenerative Focus: This platform allows the company to target specific mRNA sequences linked to Alzheimer’s and Parkinson’s, moving OliX into a trillion-dollar market previously dominated by limited small-molecule options.
OliX’s Core Values, cp-asiRNA Platform Technology
OliX core platform technology video
This video provides an in-depth technical explanation of the cp-asiRNA platform, which is the foundational technology for OliX’s unique delivery capabilities.
Valuation Report: OliX Pharmaceuticals (2026.02.15)
1. rNPV Analysis: Sum-of-the-Parts (SOTP) Valuation
Calculated at 1 USD = 1,450 KRW. Success probabilities (PoS) reflect 2026 clinical maturation.
| Asset / Segment | Type / Status | Est. POS | rNPV Valuation |
| Metabolic (OLX702A) | MASH & Obesity (Lilly) | 32% | $1.24B (1.80T KRW) |
| Ophthalmic (OLX301A) | Dry & Wet AMD (L/O Negotiation) | 18% | $0.69B (1.00T KRW) |
| Dermatology (OLX104C) | Alopecia (L’Oreal Co-op) | 15% | $0.35B (0.51T KRW) |
| CNS Platform | Neuro (BBB Shuttle) | 8% | $0.42B (0.61T KRW) |
| Operating Assets | Cash & mCureX Equity | 100% | $0.14B (0.20T KRW) |
| Total Pipeline Value | $2.84B (4.12T KRW) |
2. Technology-Driven EBITDA & Multiples
- Global Peer Alignment: As OliX proves its multi-tissue capability, its valuation gap with global peers is expected to close.
- Target Multiples: Alnylam and Arrowhead trade at significant premiums due to platform validation. With the Lilly deal and the upcoming Ophthalmic L/O, OliX is moving from a speculative multiple toward a validated platform multiple of 20x-25x.
| Company | Delivery Platform | Market Cap (USD) | Market Cap (KRW) |
| Alnylam | GalNAc (Commercial) | ~$40.8B | ~59.2T KRW |
| Arrowhead | TRiM (Late Phase 3) | ~$8.4B | ~12.2T KRW |
| OliX | cp-asiRNA / GalNAc | ~$1.8B | ~2.6T KRW |
3. Why the “Premium” is Justified: The OliX Ecosystem
- Speed of Expansion: OliX has successfully expanded from liver to eye and brain in less than three years, demonstrating the versatility of its asymmetric siRNA design.
- Self-Funding Potential: Following the $629M Lilly milestone structure, OliX is reducing its reliance on dilutive funding, allowing it to self-fund earlier-stage CNS research.
Strategic Conclusion
- Current Status: Technical validation achieved; entering global licensing phase for non-liver assets.
“Accumulate: Re-rating Pending Clinical & Partnering Milestones”
While the rNPV-based fair value is calculated at $2.84B (4.12T KRW), a more conservative approach is recommended due to the following execution risks:
- Partnering Lead Time: Market sentiment remains cautious until a formal global licensing agreement for OLX301A (AMD) is signed.
- Platform Execution: The CNS/BBB shuttle technology is currently an ‘option value’ and requires pre-clinical proof of concept before receiving full market credit.
Final Opinion: Accumulate on Dips. Focus on a long-term hold with a realistic near-term target of $2.27B (3.30T KRW), representing a 20% execution discount until the next major licensing event.
Market Snapshot: Olix Pharm [Feb 13, 2026]
K-Bio Value Report 
댓글 남기기